Group 1 - Polen Capital's fourth-quarter 2025 investor letter indicates a challenging environment for its quality-heavy portfolio, which returned -2.5% gross of fees, lagging behind the MSCI All Country World Index's 3.3% gain [1] - The stock market experienced a significant 5% sell-off in Q4 2025 but quickly rebounded to all-time highs, reflecting a V-shaped recovery similar to that seen from April lows [1] - The portfolio's software holdings underperformed despite revenue and earnings growth, contributing to the overall performance headwinds faced by the Fund [1] Group 2 - ICON Public Limited Company (NASDAQ:ICLR) is highlighted as a stock in the Polen Global Growth Strategy, with a market capitalization of $8.56 billion [2] - The stock of ICON Public Limited Company closed at $110.03 per share on March 09, 2026, with a one-month return of -23.88% and a 52-week loss of 37.40% [2] - Polen Global Growth Strategy decided to exit its position in ICON Public Limited Company due to short to intermediate-term growth challenges, reallocating to opportunities with stronger business momentum [3] Group 3 - ICON Public Limited Company is not among the 40 most popular stocks among hedge funds heading into 2026, with 41 hedge fund portfolios holding the stock at the end of Q4, down from 43 in the previous quarter [4] - While acknowledging ICON's potential, the strategy suggests that certain AI stocks may offer greater upside potential and less downside risk [4]

Core Viewpoint - ICON Public Limited Company (NASDAQ:ICLR) is currently viewed as a compelling investment opportunity despite ongoing internal accounting investigations and recent stock price adjustments by analysts [2][3]. Group 1: Analyst Upgrades - Jefferies analyst David Windley upgraded ICON from Hold to Buy, lowering the price target from $175 to $135, citing the stock's current valuation as "hard to ignore" [2]. - TD Cowen analyst Charles Rhyee also upgraded ICON from Hold to Buy, with a revised price target of $120, down from $183, suggesting that the recent selloff related to the internal accounting investigation is overdone [3]. Group 2: Internal Investigation - ICON disclosed an internal investigation initiated by the Audit Committee in October 2025, focusing on revenue recognition practices from fiscal years 2023 to 2025 [4]. - Preliminary findings suggest that revenue for 2023 and 2024 may have been overstated by less than 2% for each year, and the company expects to report one or more material weaknesses in internal controls [4]. Group 3: Company Overview - ICON provides outsourced development and commercialization services to pharmaceutical, biotechnology, and medical device companies globally [5].

Core Viewpoint - ICON Public Limited Company (NASDAQ:ICLR) is considered a cheap healthcare stock with potential for investment as it heads into 2026, maintaining a 'Market Perform' rating and a price target of $175 by BMO Capital [1][4]. Group 1: Company Performance and Outlook - The company is experiencing elevated cancellation rates, which are expected to persist in the upcoming quarters, although it is believed to have passed through its worst period [4]. - ICON is focusing on increasing investments in automation and agentic AI, which may enhance its operational efficiency [2]. - The company has a one-year median price target of $213.50, indicating an upside potential of nearly 15% from its current levels [5]. Group 2: Analyst Insights - BMO Capital initiated coverage on ICON on November 13, maintaining a 'Market Perform' rating and a price target of $175, reflecting a cautious but optimistic outlook [4]. - Analysts covering the stock generally have a 'Buy' or equivalent rating, suggesting a positive sentiment towards ICON's future performance [5].

Core Insights - Brown Capital Management's second quarter 2025 investor letter highlights a significant rally in international stocks, particularly following a global stock market sell-off at the beginning of the quarter due to Liberation Day on April 2, and a subsequent 90-day tariff reprieve [1] Group 1: Market Performance - The MSCI ACWI ex US index increased by 12.30% and the MSCI EAFE index rose by 12.07% during the second quarter of 2025 [1] - The Brown Capital Management International All-Company Strategy outperformed both international equity indexes in this quarter [1] Group 2: Company Focus - ICON Public Limited Company - ICON Public Limited Company (NASDAQ:ICLR) is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, and medical-device companies [3] - The stock of ICON Public Limited Company experienced a one-month return of -8.66% and a 52-week loss of 43.09%, closing at $162.53 per share on September 25, 2025, with a market capitalization of $12.64 billion [2][3] - ICON has been a part of the International All Company strategy for over a decade, providing services that include management of clinical trials, bioanalytical and clinical lab services, data analytics, regulatory consulting, and marketing strategies [3]